A small number of patients taking GLP-1 weight loss medications have experienced loss of vision, but researchers say they have not established a direct link to the drugs.

A new study published in JAMA Opthalmology focused on patients using semaglutide, which is marketed under the brand names Wegovy and Ozempic, and tirzepatide, which is marketed as Mounjaro and Zepbound.

The drugs, originally used to treat diabetes, have soared in popularity after they were found to be effective for weight loss.

Researchers looked at the........

© The Hill